What are the two main cutaneous subsets of systemic sclerosis?

Limited cutaneous systemic sclerosis, with skin thickening confined mainly to the hands, forearms, and face, and diffuse cutaneous systemic sclerosis, with more widespread skin involvement and earlier internal-organ disease.

Why are autoantibodies important in systemic sclerosis?

Specific autoantibodies such as anti-centromere, anti-topoisomerase I, and anti-RNA polymerase III tend to associate with particular disease patterns and organ-complication risks, helping characterize the disease.

Systemic Sclerosis (Scleroderma)

Systemic sclerosis is a systemic autoimmune connective tissue disease characterized by the triad of small-vessel vasculopathy, autoimmunity, and progressive fibrosis of the skin and internal organs. It ranges from limited cutaneous forms, in which skin thickening is largely confined to the extremities and face, to diffuse cutaneous disease with more widespread skin and early internal-organ involvement.

Definition

Systemic sclerosis is an autoimmune disease defined by immune activation, obliterative small-vessel vasculopathy, and excessive deposition of extracellular matrix (fibrosis) affecting the skin and internal organs such as the lungs, gastrointestinal tract, heart, and kidneys.

Scope

This entry covers systemic sclerosis as a clinical entity within the systemic autoimmune diseases: its vascular, immune, and fibrotic mechanisms, its characteristic autoantibodies, the distinction between limited and diffuse cutaneous subsets, and how classification criteria define study populations. It is reference-educational and does not provide diagnostic or treatment instructions.

Key concepts

Vasculopathy and Raynaud phenomenon
Fibroblast activation and tissue fibrosis
Limited versus diffuse cutaneous subsets
Anti-centromere antibodies
Anti-topoisomerase I (anti-Scl-70) antibodies
Anti-RNA polymerase III antibodies
Interstitial lung disease and pulmonary hypertension
Scleroderma renal crisis

Mechanisms

Systemic sclerosis is understood as the interplay of three processes: an early obliterative vasculopathy of small vessels, autoimmune activation with disease-specific autoantibodies, and progressive fibrosis driven by activated fibroblasts and myofibroblasts that deposit excess collagen and other matrix proteins. Endothelial injury, immune cell infiltration, and profibrotic mediators such as transforming growth factor beta link these processes. Distinct autoantibodies, including anti-centromere, anti-topoisomerase I, and anti-RNA polymerase III, correlate with cutaneous extent and organ-complication risk (Allanore et al., 2015; Denton & Khanna, 2017).

Clinical relevance

Systemic sclerosis illustrates how autoimmune vasculopathy and fibrosis combine to produce multi-organ disease, with Raynaud phenomenon, skin thickening, and internal-organ fibrosis as recognizable features. The 2013 ACR/EULAR classification criteria define consistent research populations rather than diagnose individuals (van den Hoogen et al., 2013). This entry describes the disease conceptually and is not a basis for individual diagnostic or therapeutic decisions.

Epidemiology

Systemic sclerosis is uncommon and shows a clear female predominance, with onset typically in middle adulthood. It is among the connective tissue diseases with the highest disease-related mortality, with interstitial lung disease and pulmonary hypertension being leading causes of death (Allanore et al., 2015; Denton & Khanna, 2017).

Evidence & guidelines

Classification of systemic sclerosis for research uses the 2013 ACR/EULAR criteria, which incorporate skin involvement, vascular features, fingertip lesions, telangiectasia, nailfold capillary changes, lung involvement, and specific autoantibodies (van den Hoogen et al., 2013). These criteria standardize study populations and are distinct from clinical diagnosis. Management recommendations are issued separately by EULAR and other bodies and are not summarized here.

History

Localized hardening of the skin was described long before its systemic nature was understood; the recognition of internal-organ fibrosis and of disease-specific autoantibodies in the twentieth century established scleroderma as a systemic autoimmune disease. The 1980 ACR (then ARA) preliminary criteria were superseded by the more sensitive 2013 ACR/EULAR classification criteria.

Debates

How should systemic sclerosis be subclassified?: Classification by extent of skin involvement (limited versus diffuse cutaneous) is long-established, but autoantibody-based and molecular subsetting may better predict organ-complication risk, and the optimal framework for stratifying patients remains under discussion.

Key figures

Christopher Denton
Yannick Allanore
John Varga

Seminal works

allanore-2015
denton-2017
van-den-hoogen-2013

Frequently asked questions

What are the two main cutaneous subsets of systemic sclerosis?: Limited cutaneous systemic sclerosis, with skin thickening confined mainly to the hands, forearms, and face, and diffuse cutaneous systemic sclerosis, with more widespread skin involvement and earlier internal-organ disease.
Why are autoantibodies important in systemic sclerosis?: Specific autoantibodies such as anti-centromere, anti-topoisomerase I, and anti-RNA polymerase III tend to associate with particular disease patterns and organ-complication risks, helping characterize the disease.